Article Text

Download PDFPDF
Basic science for the chest physician
MicroRNAs in lung diseases
  1. Tom Pagdin,
  2. Paul Lavender
  1. Department of Asthma, Allergy and Respiratory Science, MRC/Asthma UK Centre in Allergic Mechanisms of Asthma, King's College London, Guy's Hospital, London, UK
  1. Correspondence to Dr Paul Lavender, Department of Asthma, Allergy & Respiratory Science, MRC/Asthma UK Centre in Allergic Mechanisms of Asthma, King's College London, 5th Floor Tower Wing, Guy's Hospital, London SE1 9RT, UK; paul.lavender{at}kcl.ac.uk

Abstract

The advent of RNA sequencing technology has stimulated rapid advances in our understanding of the transcriptome, including discovery of the vast RNA complement generated by transcript splice variation and the expansion of our knowledge of non-coding RNAs. One non-coding RNA subtype, microRNAs (miRNAs), are particularly well studied, primarily because of their important roles as post-transcriptional gene regulators. The first miRNA was identified in the early 1990s and there are now thought to be around 1000 distinct miRNAs in man, with each cell type expressing a distinct repertoire. Increasing evidence has implicated miRNAs as having causative roles in a variety of lung diseases and has driven investigations into their potential as therapeutic targets.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Competing interests None.

  • Provenance and peer review Commissioned; internally peer reviewed.